Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
This is a randomized, placebo-controlled, multi-center, double-blinded, Phase III study to determine the efficacy and safety of patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy.
Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
COMBINATION_PRODUCT: Toripalimab combined with cisplatin and paclitaxel|COMBINATION_PRODUCT: Placebo combined with cisplatin and paclitaxel
To compare IRC-assessed events-free survival (EFS) in 2 arms, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed approximately up to 60 months
pathologically complete remission (pCR) rate, To compare the percentage of patients who achieved pCR in the 2 arms, pCR rate was defined as the percentage of subjects who achieved a complete pathological response (PCR), From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed approximately up to 60 months|Investigator-assessed EFS according to RECIST v1.1, To compare Investigator-assessed events-free survival (EFS) in patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy., From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed approximately up to 60 months|Overall survival, To compare Overall survival in patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy., From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed approximately up to 60 months|1-year OS rate, To compare 1-year OS rates in patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy, from randomization to death from any cause at 1 year|3- year OS rate, To compare 3-year OS rates in patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy, from randomization to death from any cause at 3 year|5- year OS rate, To compare 5-year OS rates in patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy, from randomization to death from any cause at 5 year
This is a randomized, placebo-controlled, multi-center, double-blinded, Phase III study to determine the efficacy and safety of patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy.